The narcotic bowel syndrome: Clinical features, pathophysiology, and management

被引:150
作者
Grunkemeier, David M. S.
Cassara, Joseph E.
Dalton, Christine B.
Drossman, Douglas A. [1 ]
机构
[1] Univ N Carolina, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Ctr Funct Gastrointestinal & Motil Disorders, Chapel Hill, NC USA
关键词
D O I
10.1016/j.cgh.2007.06.013
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Narcotic bowel syndrome (NBS) is a subset of opioid bowel dysfunction that is characterized by chronic or frequently recurring abdominal pain that worsens with continued or escalating dosages of narcotics. This syndrome is underrecognized and may be becoming more prevalent. In the United States this may be the result of increases in using narcotics for chronic nonmalignant painful disorders, and the development of maladaptive therapeutic interactions around its use. NBS can occur in patients with no prior gastrointestinal disorder who receive high dosages of narcotics after surgery or acute painftil problems, and among patients with functional gastrointestinal disorders or other chronic gastrointestinal diseases who are managed by physicians who are unaware of the hyperalgesic effects of chronic opioids. The evidence for the enhanced pain perception is based on the following: (1) activation of excitatory antianalgesic pathways within a bimodal opioid regulation system, (2) descending facilitation of pain at the rostral ventral medulla and pain facilitation via dynorphin and cholecystokinin activation, and (3) glial cell activation that produces morphine tolerance and enhances opioid-induced pain. Treatment involves early recognition of the syndrome, an effective physician-patient relationship, graded withdrawal of the narcotic according to a specified withdrawal program, and the institution of medications to reduce withdrawal effects.
引用
收藏
页码:1126 / 1139
页数:14
相关论文
共 83 条
[1]  
Ackerman Stacey J, 2003, J Manag Care Pharm, V9, P223
[2]   Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience [J].
Amass, L ;
Ling, W ;
Freese, TE ;
Reiber, C ;
Annon, JJ ;
Cohen, AJ ;
McCarty, D ;
Reid, MS ;
Brown, LS ;
Clark, C ;
Ziedonis, DM ;
Krejci, J ;
Stine, S ;
Winhusen, T ;
Brigham, G ;
Babcock, D ;
Muir, JA ;
Buchan, BJ ;
Horton, T .
AMERICAN JOURNAL ON ADDICTIONS, 2004, 13 :S42-S66
[3]   Loss of antiallodynic and antinociceptive spinal supraspinal morphine synergy in nerve-injured rats: restoration by MK-801 or dynorphin antiserum [J].
Bian, D ;
Ossipov, MH ;
Ibrahim, M ;
Raffa, RB ;
Tallarida, RJ ;
Malan, TP ;
Lai, J ;
Porreca, F .
BRAIN RESEARCH, 1999, 831 (1-2) :55-63
[4]   Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder [J].
Brannan, SK ;
Mallinckrodt, CH ;
Brown, EB ;
Wohlreich, MM ;
Watkin, JG ;
Schatzberg, AF .
JOURNAL OF PSYCHIATRIC RESEARCH, 2005, 39 (01) :43-53
[5]   Alvimopan, a selective peripherally acting μ-opioid antagonist [J].
Camilleri, M .
NEUROGASTROENTEROLOGY AND MOTILITY, 2005, 17 (02) :157-165
[6]   A Randomized, Controlled Exploratory Study of Clonidine in Diarrhea-Predominant Irritable Bowel Syndrome [J].
Camilleri, Michael ;
Kim, Doe-Young ;
Mckinzie, Sanna ;
Kim, H. Jae ;
Thomforde, George M. ;
Burton, Duane D. ;
Low, Phillip A. ;
Zinsmeister, Alan R. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2003, 1 (02) :111-121
[7]  
CHANG L, 2002, CLIN PERSPECT GASTRO, V5, P336
[8]   Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage [J].
Chapman, GA ;
Moores, K ;
Harrison, D ;
Campbell, CA ;
Stewart, BR ;
Strijbos, PJLM .
JOURNAL OF NEUROSCIENCE, 2000, 20 (15)
[9]  
CHEN J, 1995, CHINESE J INTERN MED, V34, P46
[10]   Functional abdominal pain syndrome [J].
Clouse, Ray E. ;
Mayer, Emeran A. ;
Aziz, Qasim ;
Drossman, Douglas A. ;
Dumitrascu, Dan L. ;
Moennikes, Hubert ;
Naliboff, Bruce D. .
GASTROENTEROLOGY, 2006, 130 (05) :1492-1497